Neurology 2-Plex A (Aβ40, Aβ42)
Amyloid beta (Aβ) Assay
Advance your neurology research from discovery to diagnostics by reliably measuring Aβ40 and Aβ42.
The Quanterix Simoa® Neurology 2-Plex A (N2PA) assay is an ultrasensitive laboratory test designed to accurately measure Aβ40 and Aβ42 levels in plasma or cerebrospinal fluid (CSF) samples. This amyloid beta assay is performed using Quanterix’s Simoa® platform, a digital immunoassay technology that detects and measures low levels of biomarkers.
REQUEST MORE INFORMATION
Aβ40 and Aβ42: Biomarkers for Alzheimer’s Disease
Aβ40 and Aβ42, derived from the amyloid precursor protein (APP), are biomarkers associated with Alzheimer’s disease (AD), mild cognitive impairment, vascular dementia, and cognitive disorders.Aβ peptides, including Aβ38, Aβ40, and Aβ42, are predominantly synthesized in the brain, with Aβ40 being the major component. The cleavage of APP by beta-secretase followed by gamma-secretase leads to the production of Aβ40 and Aβ42. Accumulation of Aβ peptides, particularly Aβ40, as extracellular plaques is a hallmark of AD pathology, initiating neurodegenerative processes.
Aβ42 has garnered significant attention due to its correlation with AD onset. Its CSF levels serve as a clinically validated marker for AD diagnosis and progression. Although concentrations of Aβ42 in blood are markedly lower than in CSF, there is growing interest in measuring blood levels for research and diagnostic purposes. Thus, reliable measurement of Aβ42 necessitates high analytical sensitivity. In contrast, Aβ40, being more abundant in both CSF and blood, has also shown promise as a biomarker for AD progression, with recent studies highlighting its potential significance, particularly in the context of the Aβ42/Aβ40 ratio.
Understanding the roles of Aβ40 and Aβ42 as biomarkers is crucial for diagnosing and monitoring Alzheimer’s disease and related cognitive disorders, paving the way for improved treatment strategies and interventions.